Vertex Pharmaceuticals, a biotech company with a market cap of $104.6 billion, focuses on therapies for diseases like cystic fibrosis. Analysts expect Q3 2025 results to show an adjusted EPS of $3.98. For fiscal 2025, an adjusted EPS of $15.84 is predicted, a significant increase from the previous year’s loss.

Shares of Vertex Pharmaceuticals have fallen 15.6% over the past year, underperforming the S&P 500 and Health Care Select Sector SPDR Fund. Despite better-than-expected Q2 results, the company’s shares dropped 20.6% due to the halt of a painkiller development and scrapped expansion plans for nerve pain treatment.

Analysts give Vertex Pharmaceuticals a “Moderate Buy” rating, with a consensus price target of $491.52. Of the 33 analysts covering the stock, 18 recommend a “Strong Buy,” while one suggests a “Strong Sell.” The average target price indicates a potential upside of 19.9% from current levels.

Read more at Yahoo Finance: What To Expect From Vertex Pharmaceuticals’ Report